Health Canada has conditionally authorized the use of lecanemab, a drug designed to slow the progression of early-stage Alzheimer’s disease, prompting inquiries about its efficacy and accessibility in Canada. Lecanemab, an artificial antibody administered through intravenous infusion, specifically targets the accumulation of amyloid plaque in the brain, a characteristic feature of Alzheimer’s disease.
While lecanemab does not provide a cure and cannot reverse the disease or restore lost memories, it marks the first disease-modifying Alzheimer’s treatment approved for use in Canada, as noted by the Alzheimer Society of Canada. Existing medications focus on symptom management rather than altering the disease’s trajectory.
The drug’s effectiveness and potential impact on Canada’s healthcare systems are now key considerations for individuals with Alzheimer’s disease, their families, healthcare providers, and government entities.
Lecanemab, also known by the brand name Leqembi, is approved for treating mild cognitive impairment and early stages of Alzheimer’s disease. Patients must demonstrate the presence of amyloid plaque in the brain, as stated by the drug manufacturer. Additionally, individuals must undergo genetic testing to identify variants associated with adverse reactions. The treatment is restricted to patients with either a single copy or no copies of the APOE4 gene variant, as those with two copies are at higher risk of brain swelling or bleeding.
Availability of the necessary genetic testing varies among provinces and territories. To confirm eligibility for lecanemab, individuals may need specialized diagnostics such as a lumbar puncture or amyloid PET scan. Treatment involves IV infusions every two weeks, with each session lasting approximately an hour. Ongoing monitoring, typically through PET scans or MRIs, is essential to ensure safety and efficacy.
The Canadian Consortium on Neurodegeneration in Aging outlined potential side effects observed in clinical trials, including brain swelling or bleeding associated with antibody treatments like lecanemab. Dr. Howard Chertkow, scientific director of the consortium, likened lecanemab to a preliminary success rather than a definitive solution, emphasizing the need for further research to identify specific beneficiary groups.
The Alzheimer’s Society emphasized the importance of swift public funding and market availability to ensure affordability for all eligible patients. In other countries, lecanemab costs approximately $26,000 US annually. While it may take up to two years for new medications to receive public coverage post-regulatory approval, private or extended benefits could offer earlier access.
In 2024, Britain’s National Institute for Health and Care Excellence (NICE) concluded that the benefits of lecanemab were insufficient to justify the cost to the publicly funded health system, encompassing medication provision and side-effect monitoring.
